New SRIF analogs in the control of human pituitary adenomas: Perspectives

Journal of Endocrinological Investigation

Volumn 28, Issue 5 SUPPL, 2005, Pages 14-18

  Jaquet, P ^a,b   Saveanu, A ^a   Barlier, A ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b CNRS   (France)

Author keywords

Acromegaly; SRIF analogs; SRIF dopamine chimeras

Indexed keywords

ANGIOPEPTIN; BIM 23190; BIM 23197; BIM 23244; BIM 23268; BIM 23A387; CHIMERIC PROTEIN; DOPAMINE 2 RECEPTOR; HYBRID PROTEIN; KE 108; L 6796778; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; VAPREOTIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; SOMATOSTATIN;

ACROMEGALY; CELL CULTURE; CELL MEMBRANE; CELL MIGRATION; CONFERENCE PAPER; DIMERIZATION; DISEASE CONTROL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG INHIBITION; DRUG SYNTHESIS; HUMAN; HYPOPHYSIS ADENOMA; LONG TERM CARE; PROTEIN EXPRESSION; TREATMENT RESPONSE; ADENOMA; HYPOPHYSIS TUMOR; REVIEW;

ADENOMA; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; OCTREOTIDE; PITUITARY NEOPLASMS; SOMATOSTATIN;

EID: 27744609322     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003, 24: 28-47.
2. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999, 20: 157-98.
3. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001, 28: 836-46.
4. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24: 389-427.
5. Jaquet P, Ouafik L, Saveanu A, et al. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 1999, 84: 3268-76.
6. Jaquet P, Saveanu A, Gunz G, et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000, 85: 781-92.
7. Shimon I, Van X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997, 100: 2386-92.
8. Zatelli MC, Piccin D, Bottoni A, et al. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab 2004, 89: 5181-8.
9. Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 1999, 48: 77-85.
10. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982, 31: 1133-40.
11. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002, 87: 3013-8.
12. Moreau JP, Kim S, Dong JZ, et al. Improved analogs and novel delivery systems for somatostatin octapeptides. Metabolism 1996, 45: 24-6.
13. Gillespie TJ, Erenberg A, Kim S, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther 1998, 285: 95-104.
14. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994, 135: 2814-7.
15. Coy DH, Taylor JE. Receptor-specific somatostatin analogs: correlations with biological activity. Metabolism 1996, 45: 21-3.
16. Kreienkamp HJ, Akgun E, Baumeister H, Meyerhof W, Richter D. Somatostatin receptor subtype 1 modulates basal inhibition of growth hormone release in somatotrophs. FEBS Lett 1999, 462: 464-6.
17. Zatelli MC, Piccin D, Tagliati F, et al. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolacttn (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab 2003, 88: 2797-802.
18. Zatelli MC, Tagliati F, Piccin D, et al. Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 2002, 297: 828-34.
19. Florio T, Morini M, Villa V, et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003, 144: 1574-84.
20. Rohrer SP, Birzin ET, Mosley RT, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998, 282: 737-40.
21. Hocart SJ, Jain R, Murphy WA, Taylor JE, Coy DH. Highly potent cyclic disulfide antagonists of somatostatin. J Med Chem 1999, 42: 1863-71.
22. Reubi JC, Eisenwiener KP, Rink H, Waser B, Macke HR. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002, 456: 45-9.
23. Crider AM. Recent advances in the development of non-peptide somatostatin receptor ligands. Mini Rev Med Chem 2002, 2: 507-17.
24. Saveanu A, Gunz G, Dufour H, et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001, 86: 140-5.
25. Ren SG, Taylor J, Dong J, Yu R, Culler MD, Melmed S. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 2003, 88: 4239-45.
26. Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002, 143: 4123-30.
27. Lewis I, Bauer W, Albert R, et al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 2003, 46: 2334-44.
28. Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004, 89: 1577-85.
29. van der Hoek J, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004, 89: 638-45.
30. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003, 30: 781-93.
31. Pellegrini-Bouiller I, Morange-Ramos I, Barlier A, et al. Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression. J Clin Endocrinol Metab 1996, 81: 3390-6.
32. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004, 61: 209-15.
33. Saveanu A, Lavaque E, Gunz G, et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002, 87: 5545-52.
34. Ren SG, Kim S, Taylor J, et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 2003, 88: 5414-21.
35. Bai M. Dimerization of G-protein-coupled receptors: roles in signal transduction. Cell Signal 2004, 16: 175-86.
36. Patel RC, Kumar U, Lamb DC, et al. Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci USA 2002, 99: 3294-9.
37. Angers S, Salahpour A, Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 2002, 42: 409-35.
38. Patel RC, Lange DC, Patel YC. Photobleaching fluorescence resonance energy transfer reveals ligand-induced oligomer formation of human somatostatin receptor subtypes. Methods 2002, 27: 340-8.
39. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000, 275: 7862-9.
40. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 2002, 277: 19762-72.
41. Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996, 137: 4046-9.
42. Grant M, Patel RC, Kumar U. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem 2004, 279: 38636-43.
43. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000, 288: 154-7.
44. Pfeiffer M, Koch T, Schroder H, et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 2001, 276: 14027-36.
45. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG. Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-beta-arrestin complexes after receptor endocytosis*. J Biol Chem 2001, 276: 19452-60.
46. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS. Differential affinities of visual arrestin, beta arrestin 1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 2000, 275: 17201-10.
47. Shenoy SK, Lefkowitz RJ. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 2003, 375: 503-15.
48. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Hollt V, Schulz S. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 2004, 279: 21374-82.
49. Portoghese PS. From models to molecules: opioid receptor dinners, bivalent ligands, and selective opioid receptor probes. J Med Chem 2001, 44: 2259-69.
50. George SR, O'Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002, 1: 808-20.
51. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 2004, 66: 1-7.